By submitting this form, you are agreeing to the Terms of Use and Privacy Policy.
Coming Soon
A drug called prochlorperazine maleate is used to treat nausea and vomiting that are brought on by different illnesses such chemotherapy, radiation therapy, and surgery. It is a member of the phenothiazines drug class, which inhibits the brain’s dopamine receptors to produce its desired effects.
There are several ways to get prochlorperazine maleate, including tablets, capsules, and injections. The individual’s condition and reaction to treatment will determine the dosage and frequency of administration.
Prochlorperazine Maleate commonly causes sleepiness, dizziness, dry mouth, blurred vision, constipation, and muscle stiffness as adverse effects. Seizures, abnormal heartbeats, and allergic responses are more severe adverse effects that can happen.
When taking Prochlorperazine Maleate, it’s crucial to adhere to your doctor’s recommendations and report any adverse effects right away. Additionally, let your doctor know if you are taking any other drugs since they can interfere with prochlorperazine maleate.
The dosage is determined by the patient’s age, health, and treatment response.. The dosage should not be raised or taken more frequently than prescribed; the drug is typically given three to four times each day.
Global Prochlorperazine Maleate market accounted for $XX Billion in 2022 and is anticipated to reach $XX Billion by 2030, registering a CAGR of XX% from 2023 to 2030.
The generic form of Compazine a Reference Listed Drug (RLD), Prochlorperazine Maleate Tablets USP, 5 mg and 10 mg, have been released by ANI Pharmaceuticals. In technological cooperation with Biophore India Pharmaceuticals Pvt.
Ltd., the pills were created. To treat severe nausea or vomiting, use prochlorperazine maleate tablets. The current annual US market for tablets containing prochlorperazine maleate.
Prochlorperazine, another medicine with low competition, is being released by ANI Pharmaceuticals, giving clients and patients access to premium generics. Prochlorperazine Maleate Tablets’ abbreviated new drug application was submitted on August in accordance with Section 505(j) of the Federal Food, Drug, and Cosmetic Act.
